DANTE Trial Shows Promise for Shorter Immunotherapy Duration in Advanced Melanoma
核心洞察
The UK DANTE phase III trial found that 80.2% of patients who stopped immunotherapy after 12 months maintained disease control, compared to 87.6% who continued treatment for two years or more.
The study represents the largest prospective trial to date evaluating optimal treatment duration for inoperable late-stage melanoma (搜索) with immunotherapy drugs like pembrolizumab and nivolumab.
While promising, the trial was underpowered due to pandemic-related recruitment challenges, meaning two-year treatment should remain the current standard.
Reducing immunotherapy treatment duration from two years to one year for advanced melanoma (搜索) patients showed comparable disease control rates in a landmark UK clinical trial, potentially offering patients relief from prolonged treatment burdens while maintaining therapeutic efficacy.
The DANTE phase III trial, presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, demonstrated that 80.2% of patients who discontinued immunotherapy after 12 months continued to maintain disease control after a further 12 months. This compared to 87.6% of patients who maintained disease control after taking the drugs for two years or more, when considering a pre-defined margin of disease worsening.
Trial Design and Patient Population
The five-year study, conducted between September 2018 and March 2023, recruited 415 patients from 36 UK hospitals during their first 12 months of treatment. Upon reaching 12 months, 166 patients whose disease had not progressed were randomly assigned to either stop immunotherapy treatment or continue with the treatment for a further 12 months or longer, provided the treatment and toxicity remained manageable.
The trial focused on patients with inoperable stage 3 and stage 4 metastatic melanoma (搜索), a population that has seen transformed outcomes with the introduction of immunotherapy drugs such as pembrolizumab and nivolumab. Current standard first-line treatment involves using these immunotherapy drugs for at least two years, or for as long as the drugs continue to help patients.
Clinical Significance and Current Treatment Landscape
Melanoma (搜索) is the fifth most common skin cancer (搜索), with immunotherapy treatments transforming the outlook for patients with inoperable late-stage melanoma – which was considered untreatable just 10 years ago. While current treatments have significantly improved survival rates, there has been no strong evidence that two years is the optimal duration for controlling or shrinking tumours in patients with advanced melanoma.
Professor Sarah Danson, Chief Investigator of the DANTE trial and Professor of Medical Oncology at the University of Sheffield, explained the clinical challenge: "Reducing the amount of treatment is one of the hardest things to do because patients and clinical teams worry that 'more is best'. However, more treatment may mean more side-effects, which can be a burden to patients."
Quality of Life and Treatment Burden
Analyses of secondary endpoints revealed little difference in quality of life between patients receiving different treatment durations. This finding is particularly significant given that patients on extended immunotherapy can experience severe side effects, requiring more tests and hospital visits and sometimes inpatient admissions.
The trial included patient Jackie Summers, 77, who was diagnosed with inoperable stage 3 melanoma (搜索) in 2018. Since participating in the trial, her tumour has shrunk to about half its size, and she has seen a slow reduction in swelling, though she still wears a compression sleeve for comfort.
Study Limitations and Future Implications
Despite the promising results, challenges with recruitment arising from the pandemic led to early closure of the trial before the full sample size could be recruited. This meant the trial was underpowered, and continuing immunotherapy for at least two years should remain as standard treatment.
Michelle Collinson, Associate Professor in Clinical Trials at the Leeds Cancer Research UK Clinical Trials Unit (搜索), University of Leeds, emphasized the broader impact: "Clinical trials research is essential to improve the care and outcomes for patients globally. We are proud to have led delivery of the DANTE trial and hope the promising findings will inform further research into immunotherapy treatment for melanoma (搜索) patients."
Economic and Research Implications
Further work is currently underway to explore the cost-effectiveness of the reduced treatment duration. The research team plans to examine the data in more detail to identify whether certain patient subgroups benefited more than others from the shorter treatment approach.
The trial was funded by a National Institute for Health and Care Research (NIHR) Health Technology Assessment grant and represents the largest prospective trial to date evaluating optimal treatment duration for inoperable late-stage melanoma (搜索) with immunotherapy. The study was sponsored by Sheffield Teaching Hospitals NHS Foundation Trust and conducted by the Leeds Cancer Research UK Clinical Trials Unit (搜索) at the University of Leeds, with patient input through the Melanoma Focus Charity.